Product Description
Mechanisms of Action: ADRB3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Irritable Bowel Syndrome|Overactive Bladder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VEL-2001 | P2 |
Completed |
Overactive Bladder |
2019-04-29 |
23% |
| VEL-2002 | P2 |
Completed |
Overactive Bladder |
2019-01-24 |
24% |
| VEL-1001 | P1 |
Completed |
Overactive Bladder |
2016-12-01 |
22% |
| B3A106044 | P1 |
Completed |
Overactive Bladder |
2007-08-01 |